To appraise the clinical and cost effectiveness of lenvatinib within its marketing authorisation for advanced, unresectable, untreated hepatocellular carcinoma.
Status In progress
Process STA
ID number 1089

Provisional Schedule

Committee meeting: 1 30 May 2018
Expected publication 31 October 2018

Project Team

Project lead Stephanie Yates

Email enquiries


Key events during the development of the guidance:

Date Update
07 December 2017 Invitation to participate
23 August 2017 - 21 September 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
05 December 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance